Enhancements Meet EU GMP Standards
Curia Global, Inc., a prominent player in the global research, development, and manufacturing sector, has announced the completion of a significant upgrade to its aseptic suites located in Valladolid, Spain. This $4 million project aligns with the EU’s stringent GMP Annex 1 standards. The enhancements at the facility are primarily aimed at bolstering product integrity and reducing microbiological risks during production.
The central aspect of the upgrade involved transitioning to a fully closed system, which is designed to improve contamination control and ensure high-quality production. Among the key improvements are the installation of advanced isolators, upgrades to the HVAC systems, pharmaceutical utilities, automation, and sterilization-in-place processes.
Philip Macnabb, CEO of Curia, emphasised the company’s dedication by stating, “This investment at Valladolid reflects Curia’s commitment to delivering high-quality sterile manufacturing capabilities that align with the growth plans of our customers.”
Improved Sterile Manufacturing Capabilities
Following these enhancements, the Valladolid facility now provides greater flexibility, reliability, and speed in sterile production. The advanced closed processing system and enhanced contamination controls are expected to result in a consistent, high-quality supply at a larger scale.
These upgrades position Curia as a leading choice for complex sterile product manufacturing, meeting the high standards demanded by both regulators and customers. Curia’s ability to deliver such quality reinforces its status as a preferred partner in the industry.
Curia, with over 30 years of experience, operates an integrated network of more than 20 global sites, employing 3,100 individuals. The organisation’s services extend from drug discovery through to commercialization, encompassing integrated regulatory, analytical, and sterile fill-finish capabilities.
Curia’s expertise in small molecule, generic APIs, and biologics allows them to partner effectively with biopharmaceutical customers, facilitating the market introduction of life-changing therapies. Their scientific and process experts, along with regulatory-compliant facilities, ensure a best-in-class experience across drug substance and drug product manufacturing. Curia’s recent advancements in Valladolid are poised to accelerate research efforts and improve patient outcomes globally. For more information, visit Curia’s official website.
